ReviewNeuro-oncology practice2017
Pivotal therapeutic trials for infiltrating gliomas and how they affect clinical practice.
Review in Neuro-oncology practice, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 1 synthesis or guideline pooled it, 31 citations in OpenAlex.
- Pooled it
- A phase 2, open label, clinical trial of pre-surgical and adjuvant treatment of recurrent glioblastoma with tremelimumab and durvalumab alone and in combination.Journal of neuro-oncology · 2026Trial
- Recent advances in Tumor Treating Fields (TTFields) therapy for glioblastoma.The oncologist · 2025Review
- Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?Neuro-oncology · 2025Review
- Review
- Global post‑marketing safety surveillance of Tumor Treating Fields (TTFields) therapy in over 25,000 patients with CNS malignancies treated between 2011-2022.Journal of neuro-oncology · 2024Article
- STING agonist 8803 reprograms the immune microenvironment and increases survival in preclinical models of glioblastoma.The Journal of clinical investigation · 2024Article
- Glioblastoma Phagocytic Cell Death: Balancing the Opportunities for Therapeutic Manipulation.Cells · 2024Review
- Review
- Next Steps for Immunotherapy in Glioblastoma.Cancers · 2022Review
- Bevacizumab plus irinotecan with or without gamma knife radiosurgery after failure of concurrent chemo-radiotherapy for high-grade glioma.Journal of neuro-oncology · 2022Article
- Recurrent glioblastoma in elderly: Options and decision for the treatment.Surgical neurology international · 2022Review
- Tumor-Treating Fields for the treatment of glioblastoma: a systematic review and meta-analysis.Neuro-oncology practice · 2021Review
- Gene Therapy for the Treatment of Malignant Glioma.Advances in oncology · 2021Article
- Sonodynamic therapy in combination with photodynamic therapy shows enhanced long-term cure of brain tumor.Scientific reports · 2020Article
- Clinical neuro-oncology for the neurologist.Neurology. Clinical practice · 2020Review
- Global post-marketing safety surveillance of Tumor Treating Fields (TTFields) in patients with high-grade glioma in clinical practice.Journal of neuro-oncology · 2020Article
- Current Opinion on Molecular Characterization for GBM Classification in Guiding Clinical Diagnosis, Prognosis, and Therapy.Frontiers in molecular biosciences · 2020Review
- Sonodynamic Therapy for Gliomas. Perspectives and Prospects of Selective Sonosensitization of Glioma Cells.Cells · 2019Review
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The therapeutic landscape of the management of low- and high-grade infiltrating gliomas continues to evolve. Daily clinical decision making in neuro-oncology clinics across the US is frequently challenging, especially for anaplastic and low grade primary brain tumors. The focus of this review is centered on treatments which are approved by the FDA and/or featured in the NCCN Guidelines. Systemic therapy trials using a variety of agents such as temozolomide, bevacizumab, and procarbazine, lomustine, vincristine (PCV), and lastly trials of local therapies including surgical trials using carmustine impregnated wafers as well as trials investigating the administration of tumor treating fields are evaluated. Pivotal trials on the treatment of the primary brain tumors are discussed in detail along with associated correlative studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.